A renowned Spanish laboratory presented the results of clinical tests that show a dramatic reduction in the progression of moderate Alzheimer’s Disease (AD) patients, in a new step towards an innovative approach to fight this neurodegenerative disease.
At the Clinical Trials on Alzheimer’s Disease (CTAD) congress last 27 October in Barcelona, Laboratorios Grifols’ CEO Víctor Grifols said the results “open a new path in the treatment of Alzheimer’s Disease” and remarked that his company “will continue to explore the potential of plasma proteins and plasma exchange in subsequent studies.”
We find some excitement about this because the pattern of treatment is similar to our own success.